November 5, 2007New England Journal of Medicine
Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis
Key result
Antiplatelet therapy for myocardial ischemia requires balancing the reduction of coronary thrombosis against the increased risk of hemorrhage.
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Highlights the clinical challenge of balancing ischemic and bleeding risks when intensifying antiplatelet therapy.
Key Points
- This research explores the balance between the benefits of antiplatelet therapy and the risks of bleeding in myocardial ischemia management.
- Examined pathways of antiplatelet drug action on platelet aggregation and activation.
- Evaluated risks of hemorrhage versus the benefits of reducing coronary thrombosis.
- Intensified platelet inhibition increasingly reduces coronary thrombosis risk but raises hemorrhage risk.
- Findings suggest a need for careful management strategies in clinical settings.
PICO
P
Population
Myocardial ischemia
I
Intervention / Comparator
Antiplatelet therapy
Highlights the clinical challenge of balancing ischemic and bleeding risks when intensifying antiplatelet therapy.
Cite This Study
Deepak L. Bhatt (2007) conducted an editorial in Myocardial ischemia. Antiplatelet therapy was evaluated. Antiplatelet therapy for myocardial ischemia requires balancing the reduction of coronary thrombosis against the increased risk of hemorrhage.